Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 6/2016

01-06-2016 | Original Article

Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study

Authors: R. Rizzoli, C.-L. Benhamou, J. Halse, P. D. Miller, I. R. Reid, J. A. Rodríguez Portales, C. DaSilva, R. Kroon, N. Verbruggen, A. T. Leung, D. Gurner

Published in: Osteoporosis International | Issue 6/2016

Login to get access

Abstract

Summary

The efficacy and safety of weekly oral odanacatib (ODN) 50 mg for up to 8 years were assessed in postmenopausal women with low bone mineral density (BMD). Treatment with ODN for up to 8 years resulted in continued or maintained increases in BMD at multiple sites and was well tolerated.

Introduction

ODN is a selective inhibitor of cathepsin K. In a 2-year phase 2b study (3/10/25/50 mg ODN once weekly [QW] or placebo) and extensions (50 mg ODN QW or placebo), ODN treatment for 5 years progressively increased BMD and decreased bone resorption markers in postmenopausal women with low BMD (ClinicalTrials.​gov NCT00112437).

Methods

In this prespecified interim analysis at year 8 of an additional 5-year extension (years 6 to 10), patients (n = 117) received open-label ODN 50 mg QW plus weekly vitamin D3 (5600 IU) and calcium supplementation as needed. Primary end points were lumbar spine BMD and safety. Patients were grouped by ODN exposure duration.

Results

Mean (95 % confidence interval [CI]) lumbar spine BMD changes from baseline were 4.6 % (2.4, 6.7; 3-year continuous ODN exposure), 12.9 % (8.1, 17.7; 5 years), 12.8 % (10.0, 15.7; 6 years), and 14.8 % (11.0, 18.6; 8 years). Similar patterns of results were observed for BMD of trochanter, femoral neck, and total hip versus baseline. Geometric mean changes from baseline to year 8 for bone resorption markers were approximately −50 % (uNTx/Cr) and −45 % (sCTx), respectively (all groups); bone formation markers remained near baseline levels. No osteonecrosis of the jaw, delayed fracture union, or morphea-like skin reactions were reported.

Conclusions

Treatment with ODN for up to 8 years resulted in gains in BMD at multiple sites. Bone resorption markers remained reduced, with no significant change observed in bone formation markers. Treatment with ODN for up to 8 years was well tolerated.
Appendix
Available only for authorised users
Literature
1.
NIH Consensus Development Panel (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795CrossRef
2.
3.
Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475CrossRefPubMed
4.
Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57CrossRefPubMedPubMedCentral
5.
Rizzoli R, Branco J, Brandi ML et al (2014) Management of osteoporosis of the oldest old. Osteoporos Int 25:2507–2529CrossRefPubMed
6.
Whitaker M, Guo J, Kehoe T, Benson G (2012) Bisphosphonates for osteoporosis—where do we go from here? N Engl J Med 366:2048–2051CrossRefPubMed
7.
8.
Gauthier JY, Chauret N, Cromlish W et al (2008) The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 18:923–928CrossRefPubMed
9.
Cusick T, Chen CM, Pennypacker BL et al (2012) Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res 27:524–537CrossRefPubMed
10.
Masarachia PJ, Pennypacker BL, Pickarski M et al (2012) Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res 27:509–523CrossRefPubMed
11.
Stoch SA, Zajic S, Stone J et al (2009) Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther 86:175–182CrossRefPubMed
12.
Bone HG, McClung MR, Roux C et al (2010) Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 25:937–947PubMed
13.
Eisman JA, Bone HG, Hosking DJ et al (2011) Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 26:242–251CrossRefPubMed
14.
Langdahl B, Binkley N, Bone H et al (2012) Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res 27:2251–2258CrossRefPubMed
15.
Sassi ML, Eriksen H, Risteli L et al (2000) Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 26:367–373CrossRefPubMed
16.
Rünger TM, Adami S, Benhamou CL et al (2012) Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. J Am Acad Dermatol 66:e89–e96CrossRefPubMed
17.
Peroni A, Zini A, Braga V, Colato C, Adami S, Girolomoni G (2008) Drug-induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol 59:125–129CrossRefPubMed
18.
Kawalilak CE, Johnston JD, Olszynski WP, Kontulainen SA (2014) Characterizing microarchitectural changes at the distal radius and tibia in postmenopausal women using HR-pQCT. Osteoporos Int 25:2057–2066CrossRefPubMed
19.
Seeman E, Delmas PD, Hanley DA et al (2010) Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 25:1886–1894CrossRefPubMedPubMedCentral
20.
McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831CrossRefPubMed
21.
Cheung AM, Majumbdar S, Brixen K et al (2014) Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture, and estimated bone strength. J Bone Miner Res 29:1786–1794CrossRefPubMed
22.
Pennypacker BL, Gilberto D, Gatto NT et al (2016) Odanacatib increases mineralized callus during fracture healing in a rabbit ulnar osteotomy model. J Orthop Res 34:72–80
23.
Pennypacker BL, Chen CM, Zheng H et al (2014) Inhibition of cathepsin K increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys. J Bone Miner Res 29:1847–1858CrossRefPubMed
24.
Ominsky MS, Libanati C, Niu QT et al (2015) Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab. J Bone Miner Res 30:1280–1289CrossRefPubMed
25.
Brixen K, Chapurlat R, Cheung AM et al (2013) Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab 98:571–580CrossRefPubMed
26.
Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Vaananen HK (2006) Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab 52:499–509PubMed
27.
Pennypacker B, Shea M, Liu Q et al (2009) Bone density, strength, and formation in adult cathepsin K (−/−) mice. Bone 44:199–207CrossRefPubMed
28.
Baron R, Ferrari S, Russell RG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48:677–692CrossRefPubMed
29.
Jensen PR, Andersen TL, Pennypacker BL, le Duong T, Delaissé JM (2014) The bone resorption inhibitors odanacatib and alendronate affect post-osteoclastic events differently in ovariectomized rabbits. Calcif Tissue Int 94:212–222CrossRefPubMedPubMedCentral
30.
Sims NA, Ng KW (2014) Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib. Curr Osteoporos Rep 12:98–106CrossRefPubMed
31.
McClung M, Harris ST, Miller PD et al (2013) Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 126:13–20CrossRefPubMed
32.
Sutton EE, Riche DM (2012) Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis. Ann Pharmacother 46:1000–1009CrossRefPubMed
33.
McClung MR, Langdahl B, Papapoulos S et al (2015) Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis: results from the phase III Long-Term Odanacatib Fracture Trial (LOFT). IBMS BoneKEy 13:Article number:677. Abstract OC4.4
Metadata
Title
Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study
Authors
R. Rizzoli
C.-L. Benhamou
J. Halse
P. D. Miller
I. R. Reid
J. A. Rodríguez Portales
C. DaSilva
R. Kroon
N. Verbruggen
A. T. Leung
D. Gurner
Publication date
01-06-2016
Publisher
Springer London
Published in
Osteoporosis International / Issue 6/2016
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-016-3503-0

Other articles of this Issue 6/2016

Osteoporosis International 6/2016 Go to the issue

Original Article

Pre-fracture quality of life predicts 1-year survival in elderly patients with hip fracture—development of a new scoring system

Original Article

The epidemiology of fractures in Denmark in 2011

Original Article

The effects of body mass index on the hereditary influences that determine peak bone mass in mother–daughter pairs (KNHANES V)

Original Article

Combination of red cell distribution width and American Society of Anesthesiologists score for hip fracture mortality prediction

Review

Osteoporosis across chronic liver disease

Original Article

Safety and clinical performance of kyphoplasty and SpineJack® procedures in the treatment of osteoporotic vertebral compression fractures: a pilot, monocentric, investigator-initiated study